|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.04.26 - 13:48
|
Biogen Updates 2026 Guidance (AFX)
|
|
|
WESTON (dpa-AFX) - Biogen (BIIB) said, for 2026, it now expects adjusted EPS in a range of $14.25 to $15.25, revised from prior guidance range of $15.25 to $16.25. Biogen updated its guidance to r......
|
|
|
|
|
|
|
|
|
|
|
29.04.26 - 12:00
|
Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026 (Cision)
|
|
|
Stockholm, Sweden, April 29, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the first quarter 2026, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 26.2 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 161 million, which is an increase of approximately 68 percent compared to the royalty recorded by BioArctic for the first quarter 2025.
Eisai's results for their fourth quarter and full year FY2025 (April 2025 - March 2026)...
|
|
|
|
|
|
|
|
|
|
|
|
|
22.04.26 - 16:30
|
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade? (24/7 Wall St.)
|
|
|
Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the stock to Buy from Neutral and raised his price target to $225 from $185. The call centers on a specific sequence of pipeline readouts Yee believes can move the stock meaningfully higher heading into 2027. This ... UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
